Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibitionGabrielle S. Wong, Adam J. Bass, David Xu et al.|Nature Medicine|2018Cited by 282
TP53 Mutation Analysis in Gastric Cancer and Clinical Outcomes of Patients with Metastatic Disease Treated with Ramucirumab/Paclitaxel or Standard ChemotherapyFrancesco Graziano, Annamaria Ruzzo|Cancers|2020Cited by 24
Author Correction: Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibitionGabrielle S. Wong, Adam J. Bass, Jin Zhou et al.|Nature Medicine|2018Cited by 10